Absorption of zidovudine in patients with diarrhoea.
Many patients with AIDS have gastrointestinal complaints, including the major clinical disorder of chronic diarrhoea. The pharmacokinetics of zidovudine was studied in 9 male patients with HIV infection and diarrhoea to establish whether drug absorption was impaired in them. The peak plasma concentration and AUC after a single oral dose of 200 mg, were the same as those reported in 6 healthy male volunteers (3.1 vs 4.0 mumol.l-1 and 7.2 vs 5.2 mumol.h.l-1, respectively). Since the bioavailability of zidovudine is not particularly impaired, oral zidovudine therapy can be maintained in patients with diarrhoea.
Zorza
G
G
Department of Clinical Pharmacy, Bicetre Hospital, Paris, France.
Beaugerie
L
L
Taburet
A M
AM
Le Quintrec
Y
Y
Singlas
E
E
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000378:metabolism*; D000328:Adult; D001682:Biological Availability; D002908:Chronic Disease; D003967:Diarrhea / Q000150:complications / Q000378:metabolism*; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D015215:Zidovudine / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*
D015215:Zidovudine